On quick listen I didn't hear anything noteworthy on M-Enoxaparin. They did mention their oncology candidate getting a lot of interest (vague comment).
On a related note I heard part of Teva's call and they didn't give much detail but said their application is proceeding well but no timely and if I heard correctly they mentioned about labeling discussions.
Market Data 
Markets 
AI
